Rubella cost-effectiveness of therapy

Rubella Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating Rubella from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Case Studies

Case #1

Rubella cost-effectiveness of therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Rubella cost-effectiveness of therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Rubella cost-effectiveness of therapy

CDC on Rubella cost-effectiveness of therapy

Rubella cost-effectiveness of therapy in the news

Blogs on Rubella cost-effectiveness of therapy

Directions to Hospitals Treating Rubella

Risk calculators and risk factors for Rubella cost-effectiveness of therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Michael Maddaleni, B.S.

## Overview[edit | edit source]

When considering the financial costs of a certain disease, many different factors have to be taken into account. If there is a disease without a vaccination program, some of the costs ensued are expenditures made for treatment of acute illness, lost money from missing work, complications and chronic sequelae, and lost savings due to retardation or even death.[1]

On the other hand, diseases such as rubella, have vaccination programs in place, and a vaccination program has different costs associated with it. There are certain expenditures to make the vaccine itself as well as its administration, treatment of complications associated with the vaccine, and the cost of implementing the vaccine program.[1]

## Cost-Effectiveness of Rubella Vaccine Program[edit | edit source]

A study was completed in 1983 to show the cost effectiveness of the measles, mumps, and rubella vaccination program. In 1983, the costs without a vaccination program came to a total of approximately $1.4 billion and the cost with a vaccination program totaled approximately $14.5 million.[1] There was also a $380 million decrease in costs associated with the reduction in morbidity of rubella due to the vaccination program.[1]

There are also some specific numbers from the 1983 study that shows the significant cost benefit there is to a vaccination program. They are as follow:[1]

* Direct costs for acute rubella: $4,600,049 without vaccination program
* Direct costs for acute rubella: $51,308 with vaccination program
* Direct costs for congenital rubella syndrome: $121,002,219 without vaccination program
* Direct costs for congenital rubella syndrome: $2,420,044 with vaccination program
* Indirect costs for acute rubella: $166,984,895 without vaccination program
* Indirect costs for acute rubella: $218,376 with vaccination program
* Indirect costs for congenital rubella syndrome: $94,613,965 without vaccination program
* Indirect costs for congenital rubella syndrome: $5,113,782 with vaccination program

## References[edit | edit source]

1. ↑ 1.0 1.1 1.2 1.3 1.4 White CC, Koplan JP, Orenstein WA (1985). "Benefits, risks and costs of immunization for measles, mumps and rubella". American Journal of Public Health. 75 (7): 739–44. PMC 1646302. PMID 3923849. Unknown parameter `|month=` ignored (help); `|access-date=` requires `|url=` (help)CS1 maint: Multiple names: authors list (link)

Template:WH Template:WS